Randomized phase II open-label controlled study of EMD 72000 (matuzumab), in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects with metastatic esophago-gastric adenocarcinoma

Trial Profile

Randomized phase II open-label controlled study of EMD 72000 (matuzumab), in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects with metastatic esophago-gastric adenocarcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Matuzumab (Primary) ; Capecitabine; Cisplatin; Epirubicin
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms MATRIX-EG
  • Most Recent Events

    • 12 Nov 2008 Status changed from active, no longer recruiting to completed, as reported in ClinicalTrials.gov record.
    • 18 Feb 2008 Takeda and its partner Merck KGaA have decided to no longer jointly pursue development of matuzumab, based on the clinical findings to date.
    • 06 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top